The protective effects of pirfenidone in preventing abdominal aortic aneurysm formation

Abstract

AbstractVascular endothelial growth factor (VEGF)‐mediated angiogenesis participates in the initiation and progression of abdominal aortic aneurysm (AAA). Pirfenidone is a compound that has anti‐inflammatory and antioxidant properties and suppresses angiogenesis. Pirfenidone targets the extracellular matrix (ECM) and has therapeutic effects on fibrotic diseases. Therefore, we speculated that pirfenidone might have meaningful therapeutic effects in AAA, and the current study was designed to investigate this capacity. An AAA model was constructed in mice using a long‐term injection of angiotensin II (Ang II), followed by a 28‐day administration of 200 mg/kg/day pirfenidone. Increased maximal external diameter of the abdominal artery, promoted levels of VEGF‐A and its receptor VEGF‐R2, upregulated matrix metallopeptidases (MMP)‐2 and MMP‐9, and elevated release of pro‐inflammatory cytokines were observed in AAA mice, which were extremely repressed by 200 mg/kg pirfenidone. Human aortic endothelial cells (HAECs) were stimulated with Ang II for 1 day, in the presence or absence of pirfenidone (100 nM). Elevated expression of VEGF‐A and VEGF‐R2, facilitated proliferation, increased tube formation ability, and upregulated MMP‐2 and MMP‐9 were observed in Ang II‐stimulated HAECs, all of which were significantly rescued by 100 nM pirfenidone. Finally, the elevated levels of myeloid differentiation primary response 88 and phosphorylated nuclear factor‐kappa‐B subunit p65 observed in Ang II‐stimulated HAECs were repressed by pirfenidone. Collectively, pirfenidone alleviated AAA by inhibiting ECM degradation and ameliorating endothelial dysfunction.